SEARCH

SEARCH BY CITATION

References

  • Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511
  • Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, Kluin PM (2011) Double-hit B-cell lymphomas. Blood 117: 2319-2331
  • Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, Roman E, Jack A (2010) Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol: Off J Am Soc Clin Oncol 28: 3360-3365
  • Basso K, Klein U, Niu H, Stolovitzky GA, Tu Y, Califano A, Cattoretti G, Dalla-Favera R (2004) Tracking CD40 signaling during germinal center development. Blood 104: 4088-4096
  • Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A (2005) Reverse engineering of regulatory networks in human B cells. Nat Genet 37: 382-390
  • Calado DP, Sasaki Y, Godinho SA, Pellerin A, Kochert K, Sleckman BP, de Alboran IM, Janz M, Rodig S, Rajewsky K (2012) The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nat Immunol 13: 1092-1100
  • Callanan MB, Le Baccon P, Mossuz P, Duley S, Bastard C, Hamoudi R, Dyer MJ, Klobeck G, Rimokh R, Sotto JJ et al (2000) The IgG Fc receptor, FcgammaRIIB, is a target for deregulation by chromosomal translocation in malignant lymphoma. Proc Nat Acad Sci U S A 97: 309-314
  • Caraux G, Pinloche S (2005) PermutMatrix: A graphical environment to arrange gene expression profiles in optimal linear order. Bioinformatics 21: 1280-1281
  • Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT et al (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142: 699-713
  • Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkins lymphoma. New Engl J Med 359: 613-626
  • Choi H, Ghosh D, Nesvizhskii AI (2008) Statistical validation of peptide identifications in large-scale proteomics using the target-decoy database search strategy and flexible mixture modeling. J Proteome Res 7: 286-292
  • Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A et al (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459: 717-721
  • Cuccuini W, Briere J, Mounier N, Voelker HU, Rosenwald A, Sundstrom C, Cogliatti S, Hirchaud E, Ysebaert L, Bron D et al (2012) MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by HDT/ASCT. A bio-CORAL report. Blood 119: 4619-4624
  • Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J et al (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917
  • Dominguez-Sola D, Victora GD, Ying CY, Phan RT, Saito M, Nussenzweig MC, Dalla-Favera R (2012) The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nat Immunol 13: 1083-1091
  • Dos Santos A, Court M, Thiers V, Sar S, Guettier C, Samuel D, Brechot C, Garin J, Demaugre F, Masselon CD (2010) Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser microdissection and accurate mass and time tag proteomics. Mol Cell Proteomics 9: 1991-2004
  • Dupierris V, Masselon C, Court M, Kieffer-Jaquinod S, Bruley C (2009) A toolbox for validation of mass spectrometry peptides identification and generation of database: IRMa. Bioinformatics 25: 1980-1981
  • Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I et al (2010) Selective inhibition of BET bromodomains. Nature 468: 1067-1073
  • French CA (2012) Pathogenesis of NUT midline carcinoma. Ann Rev Pathol 7: 247-265
  • Friedberg JW (2011) Relapsed/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program 498-505
  • Gancz D, Donin N, Fishelson Z (2009) Involvement of the c-jun N-terminal kinases JNK1 and JNK2 in complement-mediated cell death. Mol Immunol 47: 310-317
  • Gilchrist A, Au CE, Hiding J, Bell AW, Fernandez-Rodriguez J, Lesimple S, Nagaya H, Roy L, Gosline SJ, Hallett M et al (2006) Quantitative proteomics analysis of the secretory pathway. Cell 127: 1265-1281
  • Gokul G, Ramakrishna G, Khosla S (2009) Reprogramming of HeLa cells upon DNMT3L overexpression mimics carcinogenesis. Epigenetics: Off J DNA Methylation Soc 4: 322-329
  • Govin J, Caron C, Escoffier E, Ferro M, Kuhn L, Rousseaux S, Eddy EM, Garin J, Khochbin S (2006) Post-meiotic shifts in HSPA2/HSP70.2 chaperone activity during mouse spermatogenesis. J Biol Chem 281: 37888-37892
  • Hao Z, Duncan GS, Seagal J, Su YW, Hong C, Haight J, Chen NJ, Elia A, Wakeham A, Li WY et al (2008) Fas receptor expression in germinal-center B cells is essential for T and B lymphocyte homeostasis. Immunity 29: 615-627
  • Hoshino A, Fujii H (2007) Redundant promoter elements mediate IL-3-induced expression of a novel cytokine-inducible gene, cyclon. FEBS Lett 581: 975-980
  • Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC et al (2006) A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. New Engl J Med 354: 2419-2430
  • Janic A, Mendizabal L, Llamazares S, Rossell D, Gonzalez C (2010) Ectopic expression of germline genes drives malignant brain tumor growth in Drosophila. Science 330: 1824-1827
  • Jazirehi AR, Vega MI, Bonavida B (2007) Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 67: 1270-1281
  • Jeon BN, Choi WI, Yu MY, Yoon AR, Kim MH, Yun CO, Hur MW (2009) ZBTB2, a novel master regulator of the p53 pathway. J Biol Chem 284: 17935-17946
  • Jin ZH, Josserand V, Razkin J, Garanger E, Boturyn D, Favrot MC, Dumy P, Coll JL (2006) Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-RGDfK-)4. Mol Imag 5: 188-197
  • Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, Dyer MJ, Siebert R, Kuruvilla J, Klasa R et al (2009) Lymphomas with concurrent BCL2 and MYC translocations: The critical factors associated with survival. Blood 114: 2273-2279
  • Kapoor A, Goldberg MS, Cumberland LK, Ratnakumar K, Segura MF, Emanuel PO, Menendez S, Vardabasso C, Leroy G, Vidal CI et al (2010) The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature 468: 1105-1109
  • Karnowski A, Chevrier S, Belz GT, Mount A, Emslie D, D'Costa K, Tarlinton DM, Kallies A, Corcoran LM (2012) B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1. J Exp Med 209: 2049-2064
  • Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, Niwa A, Chen Y, Nakazaki K, Nomoto J et al (2009) Frequent inactivation of A20 through gene mutation in B-cell lymphomas. Rinsho Ketsueki 52: 313-319
  • Keller U, Huber J, Nilsson JA, Fallahi M, Hall MA, Peschel C, Cleveland JL (2010) Myc suppression of Nfkb2 accelerates lymphomagenesis. BMC Cancer 10: 348
  • Lajmanovich A, Ribeyron JB, Florin A, Fournier A, Pasquier MA, Duley S, Chauvet M, Plumas J, Bonnefoix T, Gressin R et al (2009) Identification, characterisation and regulation by CD40 activation of novel CD95 splice variants in CD95-apoptosis-resistant, human, B-cell non-Hodgkin's lymphoma. Exp Cell Res 315: 3281-3293
  • Le Baccon P, Leroux D, Dascalescu C, Duley S, Marais D, Esmenjaud E, Sotto JJ, Callanan M (2001) Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma. Genes, Chromosomes Cancer 32: 250-264
  • Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, et al (2008) Stromal gene signatures in large-B-cell lymphomas. New Engl J Med 359: 2313-2323
  • Levy C, Frecha C, Costa C, Rachinel N, Salles G, Cosset FL, Verhoeyen E (2010) Lentiviral vectors and transduction of human cancer B cells. Blood 116: 498-500 author reply 500
  • Lindsley RC, LaCasce AS (2012) Biology of double-hit B-cell lymphomas. Curr Opin Hematol 19: 299-304
  • Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL, et al (2012) Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 109: 3879-3884
  • Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, et al (2012) The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 44: 1321-1325
  • Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L, Sims RJ III, (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proceedings of the National Academy of Sciences of the United States of America 108: 16669-16674
  • Michallet AS, Lebras L, Coiffier B (2012) Maintenance therapy in diffuse large B-cell lymphoma. Curr Opin Oncol 24: 461-465
  • Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, et al (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470: 115-119
  • Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE, Weinstock DM (2012) BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 120: 2843-2852
  • Pasqualucci L (2013) The genetic basis of diffuse large B-cell lymphoma. Curr Opin Hematol 20: 336-344
  • Reynoird N, Schwartz BE, Delvecchio M, Sadoul K, Meyers D, Mukherjee C, Caron C, Kimura H, Rousseaux S, Cole PA, et al (2010) Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J 29: 2943-2952
  • Rousseaux S, Khochbin S (2009) New hypotheses for large-scale epigenome alterations in somatic cancer cells: A role for male germ-cell-specific regulators. in Epigenomics pp. 153-161
  • Rousseaux S, Debernardi A, Jacquiau B, Vitte A.-L, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon P.-Y, Lantuejoul S, Hainaut P, et al (2013) Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci. Trans. Med. 5: 186ra66
  • Saint Fleur S, Hoshino A, Kondo K, Egawa T, Fujii H (2009) Regulation of Fas-mediated immune homeostasis by an activation-induced protein, Cyclon. Blood 114: 1355-1365
  • Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, Horsman DE, Gascoyne RD (2009) MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114: 3533-3537
  • Schlosser I, Holzel M, Hoffmann R, Burtscher H, Kohlhuber F, Schuhmacher M, Chapman R, Weidle UH, Eick D (2005) Dissection of transcriptional programmes in response to serum and c-Myc in a human B-cell line. Oncogene 24: 520-524
  • Sporn JC, Kustatscher G, Hothorn T, Collado M, Serrano M, Muley T, Schnabel P, Ladurner AG (2009) Histone macroH2A isoforms predict the risk of lung cancer recurrence. Oncogene 28: 3423-3428
  • Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, et al (2004) A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 101: 6062-6067
  • Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550
  • Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th Edition, Lyon: International Agency for Research on Cancer
  • Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, Gonzalez-Bonilla CR, Chinn P, Hanna N, Hariharan K, Jazirehi AR, et al (2009) Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res: Off J Am Assoc Cancer Res 15: 6582-6594
  • Vert JP, Foveau N, Lajaunie C, Vandenbrouck Y (2006) An accurate and interpretable model for siRNA efficacy prediction. BMC Bioinformatics 7: 520
  • Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, d'Amore ES, Montes-Moreno S, Dybkaer K, et al (2013) Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: A report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica 98: 255-263
  • Wang J, Emadali A, Le Bescont A, Callanan M, Rousseaux S, Khochbin S (2011) Induced malignant genome reprogramming in somatic cells by testis-specific factors. Biochim Biophys Acta 1809: 221-225
  • Wilker PR, Kohyama M, Sandau MM, Albring JC, Nakagawa O, Schwarz JJ, Murphy KM (2008) Transcription factor Mef2c is required for B cell proliferation and survival after antigen receptor stimulation. Nat Immunol 9: 603-612
  • Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, et al (2006) The molecular classification of multiple myeloma. Blood 108: 2020-2028
  • Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, et al (2013) Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Nat Acad Sci U S A 110: 1398-1403
  • Zippo A, De Robertis A, Serafini R, Oliviero S (2007) PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol 9: 932-944
  • Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al (2011) RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528